Evidence map›Paper›PMID 28183846›Full record

Trial reportHaematologica2017

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP

Gregor Verhoef, Tadeusz Robak, Huiqiang Huang, Halyna Pylypenko, Noppadol Siritanaratkul, Juliana Pereira, Johannes Drach, Jiri Mayer, Rumiko Okamoto, Lixia Pei and 4 more

Open access · goldAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 10 countries.

Gregor VerhoefUniversity Hospital Leuven, Belgium gregor.verhoef@uzleuven.be.
Tadeusz RobakMedical University of Lodz, Copernicus Memorial Hospital, Poland.
Huiqiang HuangSun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Halyna PylypenkoCherkassy Regional Oncology Center, Ukraine.
Noppadol SiritanaratkulFaculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Juliana PereiraHospital das Clinicas da Faculdade de Medicina da USP, São Paolo, Brazil.
Johannes DrachUniversity of Vienna, Vienna General Hospital, Austria.
Jiri MayerMasaryk University Hospital Brno, Czech Republic.
Rumiko OkamotoTokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan.
Lixia PeiJanssen Research & Development, LLC, Raritan, NJ, USA.
Brendan RooneyJanssen Research & Development, High Wycombe, Buckinghamshire, UK.
Andrew CakanaJanssen Research & Development, High Wycombe, Buckinghamshire, UK.
Helgi van de VeldeMillennium Pharmaceuticals, Inc., Boston, MA, USA.
Franco CavalliOncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Ticino, Switzerland.
Janssen (United Kingdom) · GBHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRJanssen (United States) · USMahidol University · THMasaryk University · CZMedical University of Lodz · PLMillennium Engineering and Integration (United States) · USOspedale San Giovanni Bellinzona · CHSun Yat-sen University Cancer Center · CNTokyo Metropolitan Komagome Hospital · JPVienna General Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free survival was significantly improved with VR-CAP (24.7

Indexed as

AdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleHumansKaplan-Meier EstimateLymphoma, Mantle-CellMaleMiddle AgedPrednisoneRemission InductionRituximabAntibodies, Monoclonal, Murine-DerivedCyclophosphamideDoxorubicinPrednisoneRituximabVincristine

Identifiers

PMID28183846
PMCPMC5477608
OpenAlexW2586369123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.